Zobrazeno 1 - 10
of 125
pro vyhledávání: '"refractory and relapsed"'
Autor:
Lu Gao, Li Yang, Shiyuan Zhou, Wenjuan Zhu, Yue Han, Suning Chen, Shengli Xue, Ying Wang, Huiying Qiu, Depei Wu, Xiaojin Wu
Publikováno v:
Stem Cell Research & Therapy, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Background Elderly patients with acute myeloid leukemia or myelodysplastic syndromes (AML/MDS) have historically had poor prognoses. However, there has been a recent increase in the use of allogenic hematopoietic stem cell transplantation (a
Externí odkaz:
https://doaj.org/article/deae602c27b0440ab606e46d96bb3708
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe central nervous system (CNS) is the most common site of extramedullary invasion in acute lymphoblastic leukemia (ALL), and involvement of the CNS is often associated with relapse, refractory disease, and poor prognosis. Chimeric antigen
Externí odkaz:
https://doaj.org/article/8b9cc0ae30e3499a98e8090d4f344340
Autor:
Han Yao, Cheng Zhang, Xu Tan, Jieping Li, Xiaolin Yin, Xiaojuan Deng, Ting Chen, Jun Rao, Lei Gao, Peiyan Kong, Xi Zhang
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12377-12387 (2023)
Abstract Background Refractory and relapsed acute myeloid leukemia (r/rAML) is associated with a difficult prognosis; clinical trials are typically suggested despite lack of a recognized standard of care. Combinatorial chemotherapy regimens utilized
Externí odkaz:
https://doaj.org/article/c5ec9310e0d946f4afef6df994084446
Autor:
Chen Zhang, Jili Deng, Yan Xie, Lan Mi, Weiping Liu, Xiaopei Wang, Linjun Zhao, Yuqin Song, Jun Zhu
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10351-10362 (2023)
Abstract Background Autologous stem cell transplantation (ASCT) is the standard treatment strategy for refractory or relapsed classical Hodgkin lymphoma (R/R cHL). However, a single transplantation is insufficient to cure the disease because of unfav
Externí odkaz:
https://doaj.org/article/2324eeada9cd4bddb93f9f17f764330e
Autor:
Peiling Zhang, Xiuxiu Yang, Yang Cao, Jue Wang, Mi Zhou, Liting Chen, Jia Wei, Zekai Mao, Di Wang, Yi Xiao, Haichuan Zhu, Shangkun Zhang, Tongcun Zhang, Yicheng Zhang, Jianfeng Zhou, Liang Huang
Publikováno v:
Experimental Hematology & Oncology, Vol 11, Iss 1, Pp 1-9 (2022)
Abstract Background Long-term outcome is unfavourable for relapsed/refractory (r/r) lymphoma patients who are resistant to salvage chemotherapy, even after subsequent autologous stem-cell transplantation (ASCT). Although anti-CD30 chimeric antigen re
Externí odkaz:
https://doaj.org/article/19a02804d24748968e39e1c779aa2399
Autor:
Chengtao Zhang, Da Gao, Xiaohong Wang, Xiuli Sun, Yan Yan, Yan Yang, Jingjing Zhang, Jinsong Yan
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundRefractory/relapsed acute myeloid leukemia (R/R AML) has unsatisfactory outcomes even after allogeneic hematopoietic stem cell transplantation. Long-term survival is mainly influenced by complete remission (CR) rates after induction therapi
Externí odkaz:
https://doaj.org/article/66e9760abfd245eaa77c72dcd62e58a5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tung-Lung Yang, Chin Lin, Ching-Liang Ho, Tzu-Chuan Huang, Yi-Ying Wu, Hong-Jie Jhou, Po-Huang Chen, Cho-Hao Lee
Publikováno v:
Life, Vol 13, Iss 12, p 2259 (2023)
Background: Over the last decade, many studies have assessed the efficacy of treatments for refractory/relapsed multiple myeloma (R/R MM). While combination therapies show greater efficacy than traditional methods, limited research has targeted elder
Externí odkaz:
https://doaj.org/article/172b7088250f4c6ca46c67ec5ccc7bad
Autor:
Hao Wang, Yu-chen Liu, Cheng-ying Zhu, Fei Yan, Meng-zhen Wang, Xiao-su Chen, Xiao-kai Wang, Bao-xu Pang, Yong-hui Li, Dai-hong Liu, Chun-ji Gao, Shu-jun Liu, Li-ping Dou
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-19 (2020)
Abstract Background Induction therapy for acute myeloid leukemia (AML) is an anthracycline-based chemotherapy regimen. However, many patients experience a relapse or exhibit refractory disease (R/R). There is an urgent need for more effective regimen
Externí odkaz:
https://doaj.org/article/0a8d09fde8b042bd8c36f15349c63609
Autor:
Jingxian Gu, Sining Liu, Wei Cui, Haiping Dai, Qingya Cui, Jia Yin, Zheng Li, Liqing Kang, Huiying Qiu, Yue Han, Miao Miao, Suning Chen, Shengli Xue, Ying Wang, Zhengming Jin, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Background/AimsChimeric antigen receptor (CAR) T cells for refractory or relapsed (r/r) B-cell acute lymphoblastic leukemia (ALL) patients have shown promising clinical effectiveness. However, the factors impacting the clinical response of CAR-T ther
Externí odkaz:
https://doaj.org/article/a944e1cba69d4ba8b716cb889307f8e2